Italia markets closed

JNJ Sep 2024 165.000 call

OPR - OPR Prezzo differito. Valuta in USD.
Aggiungi a watchlist
0,6800+0,1300 (+23,64%)
Alla chiusura: 11:12AM EDT
Schermo intero
Chiusura precedente0,5500
Aperto0,6000
Denaro0,4500
Domanda0,8500
Prezzo d'esercizio165,00
Scadenza2024-09-20
Min-Max giorno0,6000 - 0,6800
Contratto - Min-MaxN/D
Volume5
Open Interest2,33k
  • GlobeNewswire

    Alvotech and Teva Secure U.S. License Date for AVT04, a Proposed Biosimilar to Stelara®

    According to the settlement agreement, AVT04 (ustekinumab) can be marketed in the US, subject to regulatory approval, no later than February 21, 2025 REYKJAVIK, Iceland and TEL AVIV, Israel and PARSIPPANY, N.J., June 12, 2023 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and Teva Pharmaceuticals, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA